Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9717MR)

This product GTTS-WQ9717MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9717MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1326MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ9778MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ8372MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ7378MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ835MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ8106MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ4778MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ1960MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW